HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
BIOBOARD - SINGAPORE
IBN engineered artificial human livers for drug testing and discovery
The liver is an important target organ for drug testing because all drugs pass through it for detoxification. This is a process whereby harmful substances are reduced or removed from the body. Drugs that cannot be detoxified may cause poisoning or other lethal side effects. IBN researchers have now made it possible for companies to predict the toxicity of new drugs earlier, potentially speeding up the drug development process and reducing the cost of manufacturing. The tool they have engineered to enable this is an artificial human liver piece, which mimics the natural tissue environment closely.

IBN Executive Director Professor Jackie Y. Ying, said, “This research advance is the first drug testing model available that can sensitively predict long-term drug responses in the liver. Such predictive toxicology platforms are useful research tools that aid and accelerate the discovery of new drugs. The ability to determine drug toxicity at an early stage would lead to significant cost savings for the pharmaceutical companies and consumers.”

IBN Group Leader Professor Hanry Yu elaborated, “Most materials and devices have been designed with little attention to what the cells need. By using a cell-centered approach and translating our basic understanding of tissue behavior, we have developed liver tissue models that can simulate conditions outside the body with striking similarity to organs inside the body.”

If commercialized, IBN's liver tissue models can be developed into test kits to support drug development and pre-clinical research. In January this year, IBN collaborated with Janssen, a pharmaceutical company of Johnson & Johnson, to produce liver cells from human stem cells for drug testing. This new research project leverages on IBN's expertise in liver tissue engineering to develop an alternative source of human liver cells that are limited in supply. IBN is also working with global healthcare company Hoffman La-Roche on a new drug screening method for hepatitis viruses, which are leading causes of liver cancer.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy